Aurinia Pharmaceuticals Inc (AUPH)

[moosedogger]

zzaatt is correct- there is zero evidence that Lupkynis is overpriced:

https://financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/aurinia-announces-positive-cost-effectiveness-assessment-of-lupkynis-voclosporin-in-latest-icer-draft-evidence-report

Here's what ICER says:

Key Cost-Effectiveness Findings

ICER’s recommended health-benefit price benchmark (HBPB) range for belimumab is between $45,000-$61,000 per year, while ICER estimates that belimumab’s actual annual net US price is approximately $43,000 for patients remaining on treatment. ICER’s HBPB for voclosporin is between $72,000-$101,000 per year, while ICER estimates that voclosporin’s actual annual net US price is $92,000 for patients remaining on treatment.

The HBPB is a price range suggesting the highest US price a manufacturer should charge for a treatment, based on the amount of improvement in overall health patients receive from that treatment, when a higher price would cause disproportionately greater losses in health among other patients in the health system due to rising overall costs of health care and health insurance. In short, it is the top price range at which a health system can reward innovation and better health for patients without doing more harm than good.

https://icer.org/news-insights/press-releases/icer-publishes-evidence-report-on-therapies-for-lupus-nephritis/

Not overpriced, but definitely underutilized!